Skip to main content

Table 2 Effectiveness assumption used in the model expressed in percentage reduction in the outcome of interest

From: Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis

Intervention Outcome affected Efficacy in % Source
Acute myocardial infarction
 Aspirin 28 day mortality 22 (15, 29) [31, 36]
 ACE-inhibitor 28 day mortality 7 (2, 11) [37, 40]
 Beta-blocker 28 day mortality 13 (2, 23) [37, 40]
 Streptokinase 28 day mortality 26 (17, 31) [36]
 ASA + clopidogrel 28 day mortality 32 (17, 47) [31, 34]
 PCI 28 day mortality 61 (38, 75) [33, 36, 41]
Post-acute myocardial infarction
 Aspirin Case fatality rate 13 (2, 22) [31, 66]
 ACE-inhibitor Case fatality rate 23 (14, 30) [42]
 Beta-blocker Case fatality rate 23 (16, 30) [43]
 Statin Case fatality rate 19 (15, 24) [44, 67]
Acute ischemic stroke
 Aspirin 28 day case fatality rate 5 (1, 9) [31]
Post-acute stroke
 Aspirin Case fatality rate 16 (2, 29) [31]
 ACE-inhibitor Case fatality rate 16 (12, 30) [45]
 Statin Case fatality rate 24 (16, 37) [35]
Primary prevention of IHD and stroke
 Anti-hypertensive treatment for systolic blood pressure (>140 or >160 mmHg) Difference between actual systolic blood pressure and 115 mmHg 33 (31, 44) [40, 46, 68]
 Cholesterol lowering treatment for total cholesterol (>5.7 or >6.2 mmol/l) Serum level of total cholesterol 20 (17, 23) [27, 44]
 Combination drug treatment for absolute risk of CVD (>5, >15, >25, >35 %) Effect on the level of systolic blood pressure plus serum cholesterol plus aspirin (33) + (20) + (18) [27, 40, 44, 46, 66, 68]